FDA Approves Isembyld (Apitegromab): First Muscle-Targeted SMA Therapy

FDA Approves First Muscle-Targeted Therapy for Spinal Muscular Atrophy

Scholar Rock’s Isembyld (apitegromab) is meant to be added on top of existing SMA drugs — attacking the disease from the muscle side rather than the nerve side.

By iPharmag Editorial Desk · Sep 12, 2026 · 1 min read

Conceptual illustration of an antibody strengthening muscle fibers linked to a motor neuron

Conceptual illustration. The FDA approved Isembyld (apitegromab), the first muscle-targeted SMA therapy.

The FDA has approved Isembyld (apitegromab) from Scholar Rock — the first and only muscle-targeted treatment for spinal muscular atrophy (SMA).

Approved on September 11, 2026, Isembyld is for adults and children aged 2 and older who are already on an SMN2-targeted therapy (the existing class of SMA drugs). It’s given as a monthly infusion.

A different angle on SMA

SMA is a genetic disease in which motor neurons degenerate, causing progressive muscle weakness. Existing treatments (like nusinersen or risdiplam) work at the nerve/gene level to raise SMN protein. Apitegromab is a myostatin inhibitor — it blocks a signal that limits muscle growth, aiming to preserve and strengthen muscle directly. It’s the first therapy to show motor-function improvement as an add-on in patients already on SMN2-targeted treatment.

The evidence — and a safety note

Approval was based on the SAPPHIRE study; notably, 98% of participants elected to continue into the long-term extension (ONYX). The most common side effects were infections (upper-respiratory), vomiting, cough and headache. One signal to watch: fractures occurred in 9% of patients on the 10 mg/kg dose versus 2% on placebo. For a disease where muscle loss is central, a therapy that targets muscle is a meaningful new option. Regulatory news, not medical advice.

Frequently asked questions

How is apitegromab different from existing SMA drugs?

Existing SMA treatments work at the nerve/gene level to raise SMN protein. Apitegromab is a myostatin inhibitor that acts on muscle directly — blocking a signal that limits muscle growth — and is used as an add-on for patients already on an SMN2-targeted therapy.

Who can receive Isembyld?

Adults and children aged 2 and older with spinal muscular atrophy who are currently receiving an SMN2-targeted treatment. It is given as a monthly infusion.

This article is for general information only and is not medical advice. Consult a qualified healthcare professional for any medical decisions.